VYNE Therapeutics is a biopharmaceutical company that develops therapies for the treatment of immuno-inflammatory conditions. Co.'s primary program is VYN201, an administered pan-bromodomain and extra-terminal (BET) inhibitor to address diseases involving multiple inflammatory cell signaling pathways while providing low systemic exposure. Co.'s second program is VYN202, a BD2-selective oral small molecule BET inhibitor. VYN202 is in preclinical development for the treatment of immuno-inflammatory indications. FMX114 is Co.'s proprietary investigational combination gel formulation of tofacitinib and fingolimod that addresses both the source and cause of inflammation in atopic dermatitis.
|
Free VYNE Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 76th percentile
(ranked higher than approx. 76% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |